Mark H. Wilcox
Papers
1
Total Citations
12
H-Index
1
About
Mark H. Wilcox is a leading clinical microbiologist and infectious disease researcher whose work has fundamentally shaped the understanding and management of *Clostridioides difficile* infection (CDI). His research centers on the epidemiology, pathogenesis, and treatment of CDI, with a particular focus on antimicrobial resistance and infection prevention. Wilcox’s major contributions include pioneering the development of novel diagnostic tools, such as the automated cell cytotoxicity neutralization assay for detecting *C. difficile* toxins in stool samples—a method that has improved diagnostic accuracy and clinical decision-making. His studies have directly influenced global treatment guidelines, particularly through landmark trials evaluating new therapies like fidaxomicin and bezlotoxumab. With over 600 publications and more than 30,000 citations, Wilcox is among the most cited researchers in his field. He has also led pivotal work on antimicrobial stewardship and the role of spore-forming bacteria in healthcare settings. Notably, he chaired the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for CDI management and has received multiple awards for his contributions to clinical microbiology. His research continues to drive innovation in diagnostics and therapeutics, making him a key figure in the fight against healthcare-associated infections.
Research Focus
Key Achievements
Top Papers
- 1